Q-omics provides the consensus-scored HYDIN profile across patient tissues and cancer cell-line models. HYDIN expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HYDIN is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, HYDIN RNA expression shows 16,961 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KICH, and THYM as cancer lineages where HYDIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HYDIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HYDIN survival associations across molecular data types. HYDIN RNA expression shows survival associations in the most cancer types (21), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HYDIN RNA expression–survival associations across cancer types. High HYDIN expression shows unfavorable associations in STAD and CESC, but favorable associations in KIRP, ACC, UVM and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HYDIN RNA expression.
This table summarizes HYDIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HYDIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HYDIN shows lower tumor expression in KICH, THCA, LUAD and LUSC and higher tumor expression in KIRP and COAD. The KICH box plot shows higher HYDIN RNA expression in normal versus tumor tissue (log2 FC = −0.708, t-test p < 0.001).
This table shows molecular features associated with HYDIN in patient tissues and cancer cell lines. In patient samples, HYDIN shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HYDIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
